Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

By M. Vaduganathan, O. Vardeny, T. Michel, J. McMurray, M. Pfeffer, S. Solomon. New England Journal of Medicine, 2020

1,801 citations recorded by the source corpus.

RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain. The authors hy...

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/294e29f1cb722a9a4a040cf29d1aa70ad3124790

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Rhian M. Touyz
2. A. Marian
3. Judith Hochman

In Endocrinology, Diabetes and Metabolism

1. Rhian M. Touyz

Citations in the corpus

• The pivotal link between ACE2 deficiency and SARS-CoV-2 infection (2020, positive): “[76,77,81,82] On the other hand, several experimental data discussed above suggest the potential utility of ARBs, particularly to limit lung inflammation during viral invasion.”
• Role of pyroptosis in inflammation and cancer (2022, background): “Furthermore, activation of the renin–angiotensin–aldosterone system (RAAS) causes increased angiotensin II, which combines with the AT1 receptor to activate the NLRP3 inflammasome in kidney, lung, cardiomyocyte, and hematopoietic cells infected by SARS-CoV-2, all of which drives the maturation of do”
• COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options (2020, background): “ACE2 is a key element in the renin–angiotensin–aldosterone system (RAAS), which is critically involved in the pathophysiology of hypertension.(34) Experimental studies demonstrated that inhibition of the RAAS with ACE inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) may result in a comp”
• Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 (2020, background): “2 Owing to the high global prevalence of hypertension (estimated to be 46% among adults in the United States), the relation between antihypertensive medications and Covid-19 outcomes is very important to public health.”
• SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues (2020, neutral): “For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of ‘‘ACE inhibitors’’ in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004; Mont”
• COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection (2021, background): “ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) promote the accumulation of Ang I and Ang II, respectively, and thus favour the conversion by ACE2 to Ang (1–9) and Ang (1–7) [13].”